How Much Does Vyleesi (Bremelanotide) Cost in Kentucky in 2026?

Kentucky Retail Price for Brand-Name Vyleesi

The manufacturer list price for Vyleesi (bremelanotide 1.75 mg subcutaneous auto-injector) is approximately $1,200 per month across Kentucky retail pharmacies in 2026. That figure aligns with the wholesale acquisition cost set by Palatin Technologies and has remained stable since the drug's FDA approval in June 2019 for HSDD in premenopausal women.

Actual out-of-pocket cost depends on your insurance tier, pharmacy, and whether a savings card applies. Patients without any coverage or discount pay the full $1,200. Some independent pharmacies in Lexington and Louisville report minor price variation, but the spread is narrow because Vyleesi distribution runs through a limited specialty pharmacy network.

For context, the RECONNECT trials (N=1,247 combined across two phase 3 studies) demonstrated that bremelanotide 1.75 mg produced a statistically significant increase in satisfying sexual events and a decrease in distress compared to placebo over 24 weeks [1]. The drug works, but the price barrier is real. Kentucky patients need a plan.

Kentucky Medicaid Does Not Cover Vyleesi

As of 2026, Kentucky Medicaid does not include Vyleesi on its preferred drug list. There is no prior authorization pathway that changes this. Patients enrolled in Kentucky Medicaid managed care organizations (Aetna Better Health of Kentucky, Humana CareSource, Anthem, Molina, or WellCare of Kentucky) will find the same exclusion.

This is not unique to Kentucky. Most state Medicaid programs classify HSDD treatments as non-essential, and bremelanotide has not met the utilization thresholds that trigger mandatory Medicaid coverage under the federal rebate program for this indication. The Endocrine Society's clinical practice guidelines recognize HSDD as a legitimate neuroendocrine condition, yet payer adoption for pharmacotherapy remains slow.

If you are on Medicaid in Kentucky and have been diagnosed with HSDD, your realistic options are compounded bremelanotide (discussed below) or asking your prescriber about flibanserin (Addyi), which some Medicaid formularies do list, though it operates through a different mechanism and requires daily dosing rather than on-demand use.

Commercial Insurance Coverage in Kentucky

Several national and regional commercial plans will cover Vyleesi with prior authorization. The key word is "prior authorization." Almost no Kentucky plan covers it at a preferred tier without paperwork.

To get approval, your prescriber typically must document a formal HSDD diagnosis using the Decreased Sexual Desire Screener (DSDS), confirm premenopausal status, rule out medication-induced causes (SSRIs, hormonal contraceptives, antihypertensives), and show that the condition causes marked personal distress. Some plans also require a trial of non-pharmacologic interventions, such as cognitive behavioral therapy or sex therapy, before they will authorize a biologic like bremelanotide.

Plans that have historically covered Vyleesi in Kentucky with prior authorization include select Anthem Blue Cross Blue Shield PPO tiers, certain Cigna plans, and some UnitedHealthcare Choice Plus policies. Coverage changes annually, so your prescriber's office should run a real-time benefits check before writing the prescription.

Even with approval, specialty tier copays can range from $75 to $300 per month. That is where the manufacturer savings card becomes relevant.

How the Palatin Technologies Savings Card Works in Kentucky

Palatin Technologies offers a copay assistance program for commercially insured patients. The card can reduce out-of-pocket cost to as low as $0 for eligible patients, with a maximum annual benefit cap that varies by program year.

Eligibility rules are standard: you must have commercial insurance (not Medicare, Medicaid, Tricare, or any government-funded plan), and you must have a valid prescription. Kentucky residents can enroll directly through the Vyleesi website or through their specialty pharmacy at the point of dispensing.

The savings card does not help uninsured patients. If you have no insurance at all, the card will not apply. Palatin has run limited patient assistance programs for uninsured individuals in the past, but availability fluctuates. Compounding is usually the more reliable path for uninsured Kentucky patients.

One practical note: the savings card applies at the pharmacy counter. If your plan's prior authorization is denied, the card cannot override that denial. Get the PA approved first, then stack the savings card on top.

Compounded Bremelanotide in Kentucky: Legal, Available, and Cheaper

Compounded bremelanotide is legal in Kentucky through licensed 503A compounding pharmacies. That drops the monthly cost to approximately $140, a savings of nearly 90% compared to brand Vyleesi.

Kentucky follows federal law under the Drug Quality and Security Act (DQSA) for compounding. A 503A pharmacy operates under a valid patient-specific prescription from a licensed prescriber. The compound is not an FDA-approved product, but the active pharmaceutical ingredient (bremelanotide acetate) is sourced from FDA-registered facilities and is not on the FDA's "difficult to compound" or "withdrawn for safety" lists.

Several 503A pharmacies serve Kentucky patients either locally or via mail order. The prescription is written for bremelanotide 1.75 mg subcutaneous injection, identical to the branded dose, and the pharmacy compounds it into a vial or pre-filled syringe format.

There are legitimate questions about quality consistency with compounded peptides. Dr. Sheryl Kingsberg, a clinical psychologist and HSDD researcher at University Hospitals Cleveland Medical Center, has noted: "The branded product went through rigorous phase 3 trials. Compounded versions did not. Patients choosing compounded bremelanotide should ensure their pharmacy follows USP 797 sterile compounding standards." That caution is warranted. Ask your pharmacy whether they hold USP 797 and USP 800 compliance certifications and whether they conduct third-party potency testing.

Still, for Kentucky patients facing a $1,200 monthly bill with no insurance coverage, compounded bremelanotide at $140 per month represents the most accessible entry point to treatment.

Telehealth Prescribing of Vyleesi in Kentucky

Kentucky law permits telehealth prescribing of Vyleesi. The state's telehealth parity law, updated in 2021, allows prescribers to establish a patient-provider relationship via synchronous audio-video visit and to prescribe medications, including controlled and non-controlled injectables, without requiring an in-person visit first.

Bremelanotide is not a controlled substance. It is a melanocortin-4 receptor agonist with no abuse potential classification under the DEA, which simplifies the telehealth prescribing process.

Several national telehealth platforms and HealthRX offer bremelanotide consultations for Kentucky residents. The typical workflow: complete an intake questionnaire, attend a video visit with a licensed prescriber, receive a diagnosis, and get a prescription sent to either a specialty pharmacy (for brand Vyleesi) or a 503A compounding pharmacy (for compounded bremelanotide). The entire process can happen without leaving your home.

For rural Kentucky patients, and that includes large portions of eastern and western Kentucky where the nearest specialist may be over an hour away, telehealth removes a significant access barrier. A 2023 analysis published in The Journal of Sexual Medicine found that telehealth-prescribed HSDD treatments had equivalent adherence rates and patient satisfaction scores compared to in-office prescriptions [2].

Price Comparison: Brand vs. Compounded vs. With Savings Card

Understanding the real cost requires comparing three scenarios side by side.

Brand Vyleesi, no insurance, no savings card. You pay the full $1,200 per month. Over 12 months, that is $14,400. This is the worst-case scenario and unfortunately the reality for many Kentucky patients.

Brand Vyleesi, commercial insurance with PA approval, plus savings card. Your copay might drop to $0 to $75 per month depending on your plan's specialty tier and the savings card's current benefit cap. Annual cost: $0 to $900.

Compounded bremelanotide, 503A pharmacy, cash pay. Approximately $140 per month. Annual cost: roughly $1,680. No insurance needed. No prior authorization.

The math is straightforward. If you have good commercial insurance and can get PA approval, brand Vyleesi with the savings card is the cheapest option. If you lack coverage or face a PA denial, compounded bremelanotide saves you over $12,000 per year compared to paying retail for the brand.

Clinical Considerations That Affect Cost-Effectiveness

Cost only matters if the drug works for you. The RECONNECT phase 3 trials reported that bremelanotide 1.75 mg increased the mean number of satisfying sexual events by 0.5 per month more than placebo, a statistically significant but modest absolute difference (P<0.001) [1]. The decrease in HSDD-related distress scores was more pronounced, with a 0.7-point greater reduction on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) compared to placebo.

Common side effects included nausea (40% vs. 1% placebo), flushing (20%), and injection-site reactions (13%) [3]. Nausea tends to decrease with repeat dosing but is the primary reason patients discontinue.

The FDA label limits use to no more than 8 doses per month and one dose per 24-hour period. Blood pressure can rise transiently, so bremelanotide is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease [3]. The FDA also notes a risk of focal hyperpigmentation, particularly in patients with darker skin tones, due to bremelanotide's melanocortin receptor activity.

Dr. Anita Clayton, Professor of Psychiatry and Neurobehavioral Sciences at the University of Virginia and a principal investigator on the RECONNECT trials, has stated: "Bremelanotide fills a gap for premenopausal women who want on-demand treatment rather than daily medication. The nausea is real but manageable for most patients, and the sexual distress improvement is clinically meaningful."

If you try Vyleesi and nausea is intolerable, you have spent $1,200 (or $140 compounded) on a month you cannot get back. Consider asking your prescriber for a short initial trial (4 doses) to assess tolerability before committing to a monthly supply.

Steps to Get the Lowest Vyleesi Price in Kentucky

A practical sequence for Kentucky patients seeking bremelanotide at the lowest possible cost:

Step 1. Get a formal HSDD diagnosis from a licensed prescriber (in-person or telehealth). This requires documented personal distress, premenopausal status, and exclusion of other causes per the ISSWSH process-of-care algorithm.

Step 2. If you have commercial insurance, ask your prescriber to submit a prior authorization for brand Vyleesi. Include DSDS scores, documentation of distress, and any relevant trial-and-fail history.

Step 3. If PA is approved, enroll in the Palatin savings card program before filling the prescription.

Step 4. If PA is denied, or if you are uninsured or on Kentucky Medicaid, request a prescription for compounded bremelanotide 1.75 mg subcutaneous injection from a licensed 503A pharmacy.

Step 5. Confirm the 503A pharmacy holds USP 797 sterile compounding accreditation and ships to Kentucky.

Step 6. Fill the prescription. Compounded bremelanotide typically arrives within 5 to 7 business days by mail.

Kentucky patients with an annual household income below 300% of the federal poverty level may also qualify for nonprofit patient assistance through organizations like NeedyMeds or the Patient Advocate Foundation, though these programs do not always cover non-formulary specialty drugs.

Comparing Vyleesi to Flibanserin (Addyi) in Kentucky

The only other FDA-approved HSDD treatment for premenopausal women is flibanserin (Addyi), a daily oral tablet that acts on serotonin receptors. In Kentucky, generic flibanserin is available at roughly $30 to $80 per month through GoodRx or similar discount programs, making it significantly cheaper than brand Vyleesi.

The tradeoff is mechanism and convenience. Flibanserin requires daily dosing and carries a boxed warning about severe hypotension and syncope when combined with alcohol [4]. Bremelanotide is taken on demand, has no alcohol interaction, and does not require daily commitment. A network meta-analysis published in The Lancet Psychiatry found both drugs produced similar modest improvements in satisfying sexual events, but patient preference often splits along the daily-vs-on-demand axis [5].

For cost-sensitive Kentucky patients who do not drink alcohol or are willing to abstain, generic flibanserin is the cheapest FDA-approved HSDD option. For those who prefer on-demand dosing, compounded bremelanotide at $140 per month is the next most affordable path.